Methotrexate pen approved to treat Crohn's disease

Metoject (methotrexate) auto-injector can now be used to treat mild to moderate Crohn's disease in adults who are refractory or intolerant to thiopurines (azathioprine or mercaptopurine).

Patients with Crohn's disease can use Metoject as monotherapy or alongside corticosteroid treatment. The pen is used once weekly; initial dosing is 25mg weekly, followed by maintenance dosing of 15mg weekly.

The discontinued syringe presentation of Metoject, which was superseded by the auto-injector in 2014, was previously licensed to treat Crohn's disease.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more